{"disease":{"id":"onychomycosis","name":"onychomycosis"},"drugs":{"marketed":[{"drug_id":"ciclopirox","indication_name":"Onychomycosis Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loprox","generic_name":"CICLOPIROX","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 1","drug_class":"ciclopirox","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Onychomycosis of fingernails","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Onychomycosis of toenails","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"efinaconazole","indication_name":"Onychomycosis due to Trichophyton mentagrophytes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jublia","generic_name":"EFINACONAZOLE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":"Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes."},{"drug_id":"efinaconazole","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jublia","generic_name":"EFINACONAZOLE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":"Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes."},{"drug_id":"efinaconazole","indication_name":"Onychomycosis of toenails","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jublia","generic_name":"EFINACONAZOLE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":"Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes."},{"drug_id":"griseofulvin","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Grifulvin V","generic_name":"GRISEOFULVIN","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"Tubulin Inhibiting Agent [EPC]","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-ultramicrosize","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"FULVICIN P/G 330","generic_name":"GRISEOFULVIN, ULTRAMICROSIZE","company_name":"CHARTWELL RX","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-microsize","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GRISEOFULVIN","generic_name":"GRISEOFULVIN, MICROSIZE","company_name":"COSETTE","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"Tubulin Inhibiting Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-ultramicrocrystalline","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GRISACTIN ULTRA","generic_name":"GRISEOFULVIN, ULTRAMICROCRYSTALLINE","company_name":"WYETH AYERST","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"miconazole","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monistat","generic_name":"miconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Imidazole antifungal","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciclopirox","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loprox","generic_name":"CICLOPIROX","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 1","drug_class":"ciclopirox","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"griseofulvin-microcrystalline","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GRIFULVIN V","generic_name":"GRISEOFULVIN, MICROCRYSTALLINE","company_name":"JOHNSON AND JOHNSON","drug_phase":"marketed","molecular_target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"penlac","indication_name":"Onychomycosis due to dermatophyte","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Penlac","company_name":"9305-9954 Quebec Inc","drug_phase":"phase_2","molecular_target":"Deoxyhypusine hydroxylase, Poly [ADP-ribose] polymerase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04327622","title":"Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population","phase":"","overall_status":"COMPLETED","enrollment_count":5084,"lead_sponsor_name":"LMC Diabetes & Endocrinology Ltd.","has_results":false},{"nct_id":"NCT02549001","title":"Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":953,"lead_sponsor_name":"Polichem S.A.","has_results":false},{"nct_id":"NCT01270971","title":"Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00730405","title":"Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":582,"lead_sponsor_name":"Stiefel, a GSK Company","has_results":true},{"nct_id":"NCT02022215","title":"Efficacy and Safety Study of ME1111 in Patients With Onychomycosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT02267356","title":"A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"Viamet","has_results":true},{"nct_id":"NCT05482763","title":"Mycosis Culture Collection From Dermatological Isolated","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Rome Tor Vergata","has_results":false},{"nct_id":"NCT02933879","title":"Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"Sun Pharmaceutical Industries, Inc.","has_results":true},{"nct_id":"NCT00679965","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06327295","title":"A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"AmtixBio Co., Ltd.","has_results":false},{"nct_id":"NCT04188574","title":"A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Blueberry Therapeutics","has_results":false},{"nct_id":"NCT03382717","title":"Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Oystershell NV","has_results":false},{"nct_id":"NCT05139888","title":"Light Therapy for Onychomycosis Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"ToeFX Inc.","has_results":false},{"nct_id":"NCT05578950","title":"Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Combined Military Hospital Abbottabad","has_results":false},{"nct_id":"NCT03280927","title":"Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Dong-A ST Co., Ltd.","has_results":false},{"nct_id":"NCT06971341","title":"Study in Patients With Onychomycosis Treated With Mycoclear® and Ciclopirox","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT04993066","title":"Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus","phase":"NA","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Candela Corporation","has_results":false},{"nct_id":"NCT04961684","title":"Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Oystershell NV","has_results":false},{"nct_id":"NCT03141840","title":"Clinical Trial of Topical ABL01 Treatment of Onychomycosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Abbell AB","has_results":false},{"nct_id":"NCT02812771","title":"Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Bausch Health Americas, Inc.","has_results":true},{"nct_id":"NCT03171584","title":"Antifungal Drugs in Treatment of Onychomycosis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04940520","title":"Alpha-bisabolol for Onychomycosis Treatment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Universidade do Vale do Sapucai","has_results":false},{"nct_id":"NCT00680134","title":"Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02546258","title":"Evaluation of the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Reckitt Benckiser Healthcare (UK) Limited","has_results":false},{"nct_id":"NCT03405818","title":"An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05560841","title":"Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Karo Pharma AB","has_results":false},{"nct_id":"NCT06417983","title":"Topical Application of Essential Oils to Treat Onchomycosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Medical Life Care Planners, LLC","has_results":false},{"nct_id":"NCT07012343","title":"Exploring Different Dose-frequency Home Photodynamic Therapy Protocols Using a Novel Home-targeted LED Device for Onychomycosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT03098342","title":"Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment","phase":"NA","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT03168841","title":"Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Western University of Health Sciences","has_results":true},{"nct_id":"NCT05415852","title":"Lasers in Onychomycosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT01039883","title":"A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Stiefel, a GSK Company","has_results":false},{"nct_id":"NCT05674747","title":"Pilot Study of Swift Microwave Device for Onychomycosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Mediprobe Research Inc.","has_results":false},{"nct_id":"NCT00680095","title":"Cumulative Irritation Test","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05135910","title":"To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Hallux, Inc.","has_results":false},{"nct_id":"NCT05089409","title":"A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"AmtixBio Co., Ltd.","has_results":false},{"nct_id":"NCT04341402","title":"Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"William N Handelman","has_results":false},{"nct_id":"NCT05999474","title":"Combined Fractional CO2 Laser With Topical Tioconazole Versus Q-switched Nd:YAG Laser in the Treatment of Onychomycosis; a Randomized Controlled Trial","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT00679770","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06006455","title":"Effect of the Erchonia® LunulaLaser™ for the Treatment of Toenail Onychomycosis","phase":"NA","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Erchonia Corporation","has_results":true},{"nct_id":"NCT05809297","title":"Diode Laser and Photodynamic Therapy Vs. Ciclopirox.","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":26,"lead_sponsor_name":"Universidad Complutense de Madrid","has_results":false},{"nct_id":"NCT03072550","title":"Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"DeviceFarm, Inc.","has_results":true},{"nct_id":"NCT01014962","title":"A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Stiefel, a GSK Company","has_results":false},{"nct_id":"NCT05110638","title":"Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"SATO Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05260450","title":"Laser Treatment of Toenail Onychomycosis With a 1064 nm Nd:YAG-laser","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT04042857","title":"Safety and Efficacy of Next Science Gel on Toenail Fungus","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Next Science TM","has_results":false},{"nct_id":"NCT03244280","title":"A Study of the Systemic Absorption of MOB015B","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Moberg Pharma AB","has_results":false},{"nct_id":"NCT00679601","title":"Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05390190","title":"Radiofrequency in Onychomycosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT03814343","title":"Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Mahidol University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}